Assessment of PD-L1 expression in tumor tissue and quantification of tumor mutational burden have found limited utility as indicators of durable clinical benefit in metastatic melanoma and are not approved by the FDA as companion diagnostics (9–13). This evidence concerns the gene CD274 and neoplasm.